BML Capital Management’s PMV Pharmaceuticals PMVP Stock Holding History

BML Capital Management’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.14M	Buy	5,330,000 +10,000	+0.2%	+$12.8K	4.06%	8
2026 Q1	$6.6M	Buy	5,320,000 +28,000	+0.5%	+$35.6K	4.24%	6
2025 Q4	$6.62M	Hold	5,292,000	–	–	5.72%	5
2025 Q3	$7.41M	Buy	5,292,000 +292,000	+6%	+$404K	6.78%	6
2025 Q2	$5.3M	Buy	5,000,000 +1,252,388	+33%	+$1.23M	4.01%	9
2025 Q1	$4.08M	Buy	3,747,612 +280,928	+8%	+$381K	3.31%	10
2024 Q4	$5.23M	Buy	3,466,684 +1,777,912	+105%	+$2.82M	3.25%	11
2024 Q3	$2.52M	Buy	1,688,772 +379,375	+29%	+$586K	1.48%	14
2024 Q2	$2.12M	Buy	1,309,397 +2,907	+0.2%	+$5.24K	1.51%	14
2024 Q1	$2.22M	Buy	+1,306,490	New	+$2.44M	1.46%	15

Other funds holding PMVP

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BML Capital Management's PMVP Position: Q2 2026 in Review

BML Capital Management increased its PMV Pharmaceuticals (PMVP) stake by 0.19% in Q2 2026, buying an estimated $12.8K and bringing the position to 5,330,000 shares worth $7.14M. The position accounts for 4.06% of the portfolio, ranked #8.

BML Capital Management first reported a position in PMVP in Q1 2024 and has held it in 10 quarters since. The position peaked at $7.41M in Q3 2025. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

BML Capital Management held 5,330,000 shares of PMV Pharmaceuticals worth $7.14M as of Q2 2026.
BML Capital Management bought 10,000 PMV Pharmaceuticals shares in Q2 2026, an estimated $12.8K.
PMV Pharmaceuticals made up 4.06% of BML Capital Management's portfolio in Q2 2026, its #8 holding.
BML Capital Management first reported a position in PMV Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
BML Capital Management's PMV Pharmaceuticals position peaked at $7.41M in Q3 2025.
64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on BML Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.